🇺🇸 Triamcinolone acetonide injection in United States
11 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 11
Most-reported reactions
- Headache — 2 reports (18.18%)
- Blindness Transient — 1 report (9.09%)
- Blood Pressure Increased — 1 report (9.09%)
- Culture Wound Positive — 1 report (9.09%)
- Cushing^S Syndrome — 1 report (9.09%)
- Deep Vein Thrombosis — 1 report (9.09%)
- Drug Interaction — 1 report (9.09%)
- Dyspnoea — 1 report (9.09%)
- Feeling Hot — 1 report (9.09%)
- Herpes Zoster — 1 report (9.09%)
Other Immunology, Rheumatology, Dermatology approved in United States
Frequently asked questions
Is Triamcinolone acetonide injection approved in United States?
Triamcinolone acetonide injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Triamcinolone acetonide injection in United States?
Somdech Phra Nangchao Sirikit Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.